Navigation Links
WestPark Capital, Inc. Announces $500,000 Arrogene NanoTechnology, Inc. Offering
Date:1/20/2012

LOS ANGELES, Jan. 20, 2012 /PRNewswire/ -- WestPark Capital, Inc. announced the initial closing of a private placement for Arrogene NanoTechnology, Inc. on January 10, 2012.  A total of 500,000 Units, each Unit consisting of one share of common stock and two common stock purchase warrants, were sold, generating gross proceeds of approximately $500,000.  Proceeds from the offering will be used for working capital and research and development related to Arrogene's diagnostic and therapeutic technologies for brain, breast and lung cancer.  WestPark Capital, Inc. acted as placement agent for the offering.

This news release does not constitute an offer to sell or the solicitation of offers to buy any security and shall not constitute an offer, solicitation, or sale of any security in any jurisdiction in which such offer, solicitation, or sale would be unlawful.  The offering was made only by Confidential Private Placement Memorandum.  Copies of the Confidential Private Placement Memorandum may be obtained via written request to WestPark Capital, Inc., 1900 Avenue of the Stars, Suite 310, Los Angeles, California 90067.

About WestPark Capital, Inc.

WestPark Capital is a leading investment banking and securities brokerage firm serving the needs of private and public growth companies worldwide.  WestPark is committed to forging lasting partnerships with emerging growth companies and the investors who back them.  WestPark provides a comprehensive range of corporate finance services, including initial public offerings, follow-on offerings, private placements and corporate finance advisory services.  Additional information about WestPark Capital, Inc. is available at www.wpcapital.com or at info@wpcapital.com. Member: FINRA/SIPC

About Arrogene NanoTechnology, Inc.

Arrogene NanoTechnology is developing a new generation of diagnostic and therapeutic drugs based on a new family of nano-biopolymers.  Arrogene was founded in 2007 to commercialize a new cancer targeting technology and a proprietary molecular delivery platform that interferes with cancer targets to inhibit and finally eradicate tumor progression.  Additional information about Arrogene is available at www.arrogene.com.

Contact:
WestPark Capital, Inc.
Richard Rappaport, CEO
(310) 843-9300

 


'/>"/>
SOURCE WestPark Capital, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. WestPark Capital Announces $2.6 Million IsoRay Offering
2. WestPark Capital, Inc. Announces $2.6 Million IsoRay Offering
3. Alexza Executes $15 million Working Capital Loan with Hercules Technology Growth Capital, Inc.
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... YORK , Jan. 16, 2017 ... Densitometers Market Outlook to 2022", provides key market data ... provides value, in millions of US dollars, volume (in ... Dual Energy X-Ray Absorptiometry (DEXA) and Quantitative Ultrasound (QUS). ... shares data for each of these market segements, and ...
(Date:1/16/2017)... 16, 2017  Verathon ® Inc., a leading manufacturer and ... new GlideScope ® Spectrum TM Single-Use video laryngoscopes. ... and Ambient Light Reduction TM technology, which actively optimizes ... ... Introducing another bright idea ...
(Date:1/16/2017)... , Jan. 16, 2017 When synthetic Fentanyl ... market their product as top-rate. They offered free samples, inviting ... customer service. Soon, business was booming. ... described as 100 times more powerful than morphine, has racked ... in last 2 years. One dealer,s recorded fentanyl sales ...
Breaking Medicine Technology:
(Date:1/15/2017)... ... January 15, 2017 , ... Going above ... program that strives to better communities around the world by offering the Gensuite ... provides the opportunity for team members to become involved in a cause that ...
(Date:1/15/2017)... ... January 15, 2017 , ... San Francisco Magazine ... Bay Area counties for 2017. Almost 1,000 nominations were submitted and a little ... process. Results were announced the magazine’s January 2017 issue . , Under ...
(Date:1/14/2017)... ... January 14, 2017 , ... Healthy ... expanding line of activated charcoal products. With more and more people opting to ... products according to how they cater to specific needs. , Moody Zook focused ...
(Date:1/13/2017)... ... January 13, 2017 , ... People ... levels. Counting carbohydrates is as easy as checking the nutrition label on foods ... blood sugar levels. Despite being sugar-free, proteins can influence — either positively or ...
(Date:1/13/2017)... ... , ... With the increasing public preference for chemical-free personal ... alternatives for customers who have grown more conscious about maintaining their health and ... charcoal products, Moody Zook Chief Executive Officer Nate Ginsburg explained their company’s decision ...
Breaking Medicine News(10 mins):